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Abstract
Background: Prevalence of high risk (HR) human papillomavirus (HPV) types in the states of San Luis Potosí (SLP) and
Guanajuato (Gto), Mexico, was determined by restriction fragment length-polymorphism (RFLP) analysis on the E6 ~250
bp (E6-250) HR-HPV products amplified from cervical scrapings of 442 women with cervical intraepithelial neoplasia and
invasive carcinoma (280 from SLP and 192 from Gto). Fresh cervical scrapings for HPV detection and typing were
obtained from all of them and cytological and/or histological diagnoses were performed on 383.
Results:  Low grade intraepithelial squamous lesions (LSIL) were diagnosed in 280 cases (73.1%), high grade
intraepithelial squamous lesions (HSIL) in 64 cases (16.7%) and invasive carcinoma in 39 cases (10.2%). In the 437 cervical
scrapings containing amplifiable DNA, only four (0.9%) were not infected by HPV, whereas 402 (92.0%) were infected
HR-HPV and 31 (7.1%) by low-risk HPV. RFLP analysis of the amplifiable samples identified infections by one HR-HPV
type in 71.4%, by two types in 25.9% and by three types in 2.7%. The overall prevalence of HR-HPV types was, in
descending order: 16 (53.4%) > 31 (15.6%) > 18 (8.9%) > 35 (5.6) > 52 (5.4%) > 33 (1.2%) > 58 (0.7%) = unidentified
types (0.7%); in double infections (type 58 absent in Gto) it was 16 (88.5%) > 31 (57.7%) > 35 (19.2%) > 18 (16.3%) = 52
(16.3%) > 33 (2.8%) = 58 (2.8%) > unidentified types (1.0%); in triple infections (types 33 and 58 absent in both states) it
was 16 (100.0%) > 35 (54.5%) > 31 (45.5%) = 52 (45.5%) > 18 (27.3%). Overall frequency of cervical lesions was LSIL
(73.1%) > HSIL (16.7%) > invasive cancer (10.2%). The ratio of single to multiple infections was inversely proportional to
the severity of the lesions: 2.46 for LSIL, 2.37 for HSIL and 2.15 for invasive cancer. The frequency of HR-HPV types in
HSIL and invasive cancer lesions was 16 (55.0%) > 31 (18.6%) > 35 (7.9%) > 52 (7.1%) > 18 (4.3%) > unidentified types
(3.6%) > 33 (2.9%) > 58 (0.7%).
Conclusion: Ninety percent of the women included in this study were infected by HR-HPV, with a prevalence 1.14
higher in Gto. All seven HR-HPV types identifiable with the PCR-RFLP method used circulate in SLP and Gto, and were
diagnosed in 99.3% of the cases. Seventy-one percent of HR-HPV infections were due to a single type, 25.9% were double
and 2.7% were triple. Overall frequency of lesions was LSIL (73.1%) > HSIL (16.7%) > invasive cancer (10.2%), and the
ratio of single to multiple infections was inversely proportional to severity of the lesions: 2.46 for LSIL, 2.37 for HSIL and
2.15 for invasive cancer. The frequency of HR-HPV types found in HSIL and invasive cancer was 16 (55.0%) > 31 (18.6%)
> 35 (7.9%) > 52 (7.1%) > 18 (4.3%) > unidentified types (3.6%) > 33 (2.9%) > 58 (0.7%). Since the three predominant
types (16, 31 and 18) cause 77.9% of the HR-HPV infections and immunization against type 16 prevents type 31 infections,
in this region the efficacy of the prophylactic vaccine against types 16 and 18 would be close to 80%.
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Background
Cervical cancer (CC) is the second cause of death by can-
cer among women in the world and the first in most
developing countries [1,2]. In the year 2000, 190,000
deaths and 80% of the 500,000 new CC cases occurred in
the developing world, and Latin American countries were
among those with the highest incidence rates, together
with countries from Sub-Saharan Africa, South and South
East Asia [3]. The risk of developing CC increases with
early start of sexual activity, number of sexual partners,
prolonged use of oral contraceptives and smoking [4]. In
Mexico it is associated with poverty related factors such as
low schooling, unemployment, residence in rural areas
and lack of access to health services [5-7].
zur Hausen [8] proposed and later demonstrated [9] that
human papillomaviruses (HPV) are the infectious agents
responsible of the neoplastic transformation of the cervi-
cal epithelium. This hypothesis was validated by finding
HPV genome sequences in 99.7% of invasive CC cases
[10]. It is currently accepted that HPV is the most com-
mon sexually transmitted pathogen [11] and that infec-
tion of the cervix by 'high risk' (HR) HPV types is a
necessary factor for CC development [10,12]. Low risk
(LR) HPV types are those usually found in warts and
benign lesions whereas HR types are those found in inva-
sive CC [13].
There are 11 major LR-HPV types (designated as 6, 11, 40,
42, 43, 44, 54, 61, 70, 72, 81) and 15 major HR-HPV types
(designated as 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 68, 73, 82) [14]. The two most frequently associated
to malignancies are HR-HPV types 16 and 18. The first is
responsible for nearly 50% and the second for nearly 20%
of all invasive CC cases in the world [10,15]. Several HR-
HPV variants with higher oncogenic potential are more
prevalent in developing countries, where they appear to
contribute to the higher incidence and mortality rates. In
Mexico the probability of developing CC by the Asian-
American variant of HPV type 16 is several times higher
than by the European variant, and around 25% of invasive
CC cases are attributed to the AA variant [16].
During the year 2000 the incidence of CC in Mexico was
40.5 cases per 100,000 women over 25 years of age and
the mortality rate was 17.1 [3], which means 12 deaths
per day. In the Mexican states of San Luis Potosí (SLP) and
Guanajuato (Gto) the mortality rates for the same year
were respectively 15.5 and 21.7 [17]. Lazcano-Ponce et al.
[18] found a HPV prevalence of 16.7% in Mexican women
below 25 years of age which decreased to 3.7% in those of
25–44 years and increased to 23% in those above 65
years, and that HR-HPV types are more prevalent in all age
groups whereas LR-HPV types are less prevalent in women
under 25 years and increase with age.
In the present work we determined the prevalence of the
HR-HPV types circulating in the neighboring states of San
Luis Potosí and Guanajuato by restriction fragment length
polymorphism (RFLP) analysis with the method of Fuji-
naga et al. [19], in women with precancerous and cancer-
ous lesions of the cervix that had been diagnosed by
cytological analysis; in two thirds of them biopsies or sur-
gical specimens were obtained and the microscopic diag-
nosis confirmed.
Results
Study population
The 442 women enrolled in this study ranged from 16 to
78 years of age. Fresh cervical scrapings for HPV detection
and typing were obtained from all of them whereas cyto-
logical and/or histological diagnoses were performed on
383. Low grade intraepithelial squamous lesions (LSIL)
were diagnosed in 280 cases (73.1%), high grade intraep-
ithelial squamous lesions (HSIL) in 64 cases (16.7%) and
invasive carcinoma in 39 cases (10.2%).
Algorithm for HPV DNA amplification of cervical scrapings
Amplification of the HR-HPV E6-250 product by direct
and nested PCR was compared. Direct PCR was performed
with primer set pU 1M/2R whereas nested PCR was per-
formed in two successive reactions: in the first one
('direct') the E6-650 segment was amplified using primer
set LCRS/E7AS, whereas in the second one ('nested') a
portion of the first reaction mixture (presumed to contain
the E6-650 product) was used as template for the internal
primers (pU 1M/2R) to generate E6-250.
Amplification of 35 random samples showed that 11
(31.4%) were positive by direct PCR and 24 (68.6%) by
nested PCR. Since E6-250 detection was 2.2 times more
sensitive with nested PCR, this modality was chosen to
analyze all problem samples.
To determine the presence of HPV DNA in cervical scrap-
ings the algorithm shown in Fig. 1 was used. Each sample
is first subjected to nested PCR to successively amplify the
E6-650 and E6-250 products. If the second one is visible,
the sample is considered positive for HR-HPV (examples
in Fig. 2A) and typified by RFLP (examples in Fig. 2B and
3C). If the second product is not observed, the sample
could be either positive, inadequate or negative. To define
if it is positive it is subjected to PCR with the primer set
MY 09/11; if L1-450 is observed, the sample is considered
positive for low risk HPV and if L1-450 is not visible, the
sample may be negative or of inadequate quality and sub-
jected to PCR with the β-globin primer set. If the β-globin
product is observed the sample is considered to be ampli-
fiable but HPV-negative; if it is not visible, the sample is
considered inadequate (i.e., not amplifiable) and unde-
fined in relation to HPV infection.Infectious Agents and Cancer 2008, 3:3 http://www.infectagentscancer.com/content/3/1/3
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In the analysis of samples from women with cervical dys-
plasia and neoplasia, as is the case of this study, this algo-
rithm saves labor, time and reagents because it first
verifies the presence of HPV through nested PCR
(expected to be positive in most samples) and then the
amplificability of the HPV-negative samples (expected to
be rare) by performing a PCR assay for a single copy
housekeeping gene such as that of β-globin.
Using the algorithm for HPV detection (Fig. 1) the 437
cervical scrapings with amplifiable DNA were analyzed.
HPV infection was demonstrated in 433 samples (99.1%)
of which 402 (92.0%) corresponded to high risk viral
types (Table 1).
Algorithm for HR-HPV typing
The sizes of E6-250 products and their corresponding
restriction fragments for the seven HR-HPV types that can
be identified with the PCR-RFLP method used appear in
Table 2.
To identify HR-HPV types the algorithm of Fig. 3 was
used. The E6-250 product from each HR-HPV type has a
specific size and a single restriction site for each of the five
enzymes used, which generate two fragments of specific
sizes allowing the identification of seven of the most fre-
quent HR-HPV types. Ava II, the first enzyme used on each
HR-HPV positive sample, identifies types 16, 18 and 33
(see examples in Fig. 2A). If Ava II does not digest the E6-
250 product or does it only partially, sample aliquots are
simultaneously incubated with each of the four remaining
enzymes to identify types 31, 52, 35 and 58 (see examples
in Fig. 2C).
HR-HPV types circulating in the region
In 402 of the 435 samples with HPV infection, one to
three of the seven identifiable HR-HPV types were
detected.
The overall prevalence of HR-HPV types was, in descend-
ing order: 16 (53.4%) > 31 (15.6%) > 18 (8.9%) > 35
(5.6) > 52 (5.4%) > 33 (1.2%) > 58 (0.7%) = unidentified
types (0.7%). Types 16, 31 and 18 therefore accounted for
77.9% of all the infections whereas the other four types
accounted for only 12.9% of them. HPV type 16 predom-
inated slightly in SLP (53.3%) over Gto (52.9%), type 31
in Gto (22.3%) over SLP (10.1%), and type 18 was
equally prevalent in SLP and Gto (8.8%) (Table 3).
HR-HPV types in single and multiple infections
The overall prevalence of infections by a single HR-HPV
type was 71.4%, i.e., 2.5 times higher than that of infec-
tions by two and three types (Table 4).
The prevalence of infections by a single HR-HPV type was
slightly higher in SLP (75.0%) than in Gto (67.4%),
whereas the overall prevalence of infections by two and
three HR-HPV types was respectively 25.9% and 2.7%, of
which 22.6% and 2.4% corresponded to SLP and 29.5%
and 3.2% to Gto (Table 4).
The HR-HPV types of single, double and triple infections
as well as the combinations of viral types in multiple
infections found in all samples and per state are shown in
Table 5.
Single infections
HPV type 16 was the most prevalent (72.6%) followed by
types 18 (10.2%) and 31 (9.9%) and then by types 52
(3.3%), 33 (1.3%) = 35 (1.3%), and 58 (0.3%) (Table 5).
The descending order of frequency of the viral types in sin-
gle infections was clearly different in each state. In SLP the
type 16 (77.4%) predominated, followed by types 18
(9.4%), 31 (8.2%), 52 (2.5%), 33 (1.3%), 35 (0.6%) = 58
(0.6%). In Gto the prevalence of type 16 was lower
Algorithm for high-risk HPV detection in cervical scrapings  from women with dysplastic and neoplastic lesions Figure 1
Algorithm for high-risk HPV detection in cervical 
scrapings from women with dysplastic and neoplastic 
lesions. It checks first for the presence of HPV DNA 
through nested PCR (expected to be positive in most sam-
ples) and then for the amplificability of β-globin DNA in HPV-
negative samples (expected to be rare).
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HR-HPV DNA detection and typing Figure 2
HR-HPV DNA detection and typing. Examples of agarose gels used for detection of the E-250 products amplified by 
nested PCR, for the first stage of HR-HPV typing with Ava II, and for the second stage with Rsa I, Bgl II, Ava I and Acc I endonu-
cleases. Numbers to the left indicate the size of the DNA markers; arrows to the right indicate the size of the products ampli-
fied or the restriction fragments obtained. (A) HR-HPV DNA detection. Lane 1, 100 bp ladder. Lanes 2–18, DNA from 
different patients. Lane 19, Positive control (HeLa cell DNA). Lane 20, Negative control (no DNA). The expected E6-250 band 
appeared in the positive control and all problem samples except that of lane 8; Note the doublets in lanes 2 and 9 suggestive of 
double infection. (B) Identification of HPV types 16 and 18 by restriction with Ava II. Lanes 1 and 20, 100 bp ladder. Lanes 2 and 
3, Positive control: E6-250 product from HeLa cell DNA intact (lane 2) and treated with Ava II (lane 3). Lanes 4–19: neighbor-
ing lanes containing E6-250 products either intact or treated with Ava II. Lanes 4 and 5, Patient 322. Lanes 6 and 7, Patient 323. 
Lanes 8 and 9, Patient 324. Lanes 10 and 11, Patient 325. Lanes 12 and 13, Patient 326. Lanes 14 and 15, Patient 328. Lanes 16 
and 17, Patient 329. Lanes 18 and 19, Patient 306. Note the slightly larger size of HPV18 product and fragments, as well as total 
and partial resistance to Ava II by samples from patients 322 (lane 5) and 328 (lane 15). (C) Identification of HPV types 31, 52 
and 35. Groups of three neighboring lanes contained E6-250 products in mixtures incubated separately with Rsa I, Bgl II and Ava 
I endonucleases from each sample. Lanes 1 and 20, 100 bp ladder. Lanes 2–4, Patient 191. Lanes 5–7, Patient 197. Lanes 8–10, 
Patient 203. Lanes 11–13, Patient 209. Lanes 14–16, Patient 211. Lanes 17–19, Patient 246. Note that infections by one and two 
HPV types are clearly distinguished.
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(63.3%) and type 31 was second (13.3%), followed by
types 18 (12.5%), 52 (4.7%), 35 (2.3%) and 33 (1.6%)
(Table 5).
Multiple infections
The overall prevalence of HPV type 16 increased in double
infections and reached its maximum possible value
(100%) in triple infections (Table 6). The overall preva-
lence of HPV type 18 also increased in double infections
and was accompanied by increases of types 31, 52 and 35
and the last two types were even higher in triple infections
(Table 6). In double and triple infections of SLP the pre-
dominant types were 16, 31, 18, 35 and 52 whereas in Gto
types 16 and 31 predominated in double infections and
types 16 and 31 in the triple ones (Table 6).
Single and multiple infections and HR-HPV types in lesions 
of increasing severity
The overall frequency of cervical lesions was, in decreasing
order, LSIL (73.1%) > HSIL (16.7%) > invasive cancer
(10.2%) (Table 7). The ratio of single to multiple infec-
Table 1: Low risk- and high risk-HPV DNA detected in amplifiable samples
Sample type SLP Gto Overall
n% n% n%
HR-HPV (E6+) 212 86.5 190 99.0 402 92.0
LR-HPV (E6-, L1+) 30 12.2 1 0.5 31 7.1
HPV negative (E6-, L1-, β-globin+) 3 1.2 1 0.5 4 0.9
Total 245 100.0 192 100.0 437 100.0
HR-HPV, positive for E6-250 product of high risk HPV.
LR-HPV, low-risk HPV (negative for E6-250; positive for L1-450).
Algorithm for HR-HPV typing Figure 3
Algorithm for HR-HPV typing. The PCR-RFLP method 
used identifies seven HR-HPV types by the size of the restric-
tion fragments of the E6-250 products generated by specific 
cuts with five enzymes. Ava II is used first because it helps 
recognize types 16, 18 and 33 (16 and 18 are known to be 
the most prevalent globally). PCR products not restricted by 
Ava II are incubated separately with each of the four remain-
ing enzymes to identify the other five HR-HPV types.
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Table 2: Size of the E6-250 products and restriction fragments of the seven HR-HPV types identifieda
Enzyme HR-HPV type
16 18 31 33 35 52 58
Total length (bp) 238 268 232 244 232 231 244
Ava II 157/81 172/96 NC 136/108 NC NC NC
Rsa I NC NC 117/115 NC NC NC NC
Ava IN C N C N C N C 1 8 6 / 4 6 N C N C
Bgl II NC NC NC NC NC 176/55 NC
Acc IN C N C N C N C N C N C 1 2 6 / 1 1 8
aTaken from Hwang [26].
NC, not cut.Infectious Agents and Cancer 2008, 3:3 http://www.infectagentscancer.com/content/3/1/3
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tions was inversely proportional to the severity of the
lesions: 2.46 for LSIL, 2.37 for HSIL and 2.15 for invasive
cancer (Table 8).
The frequency of HR-HPV types found in the cervical HSIL
and invasive cancer (n = 140) was, in decreasing order, 16
(55.0%) > 31 (18.6%) > 35 (7.9%) > 52 (7.1%) > 18
(4.3%) > unidentified types (3.6%) > 33 (2.9%) > 58
(0.7%) (Table 9).
Discussion
Studies on the prevalence of HPV cervical infection in
Mexico are scarce [7,20-22] and information on HR-HPV
prevalence is even scarcer [12,22] or deals only with HPV
types 16 and 18 [23,24].
Since our aim was to determine the prevalence of the HR-
HPV types causing cervical infections in the states of SLP
and Gto, the study included women with cervical intraep-
ithelial lesions (73.1% low grade, 16.7% high grade and
10.2% invasive carcinoma), expected to be HPV-positive.
This prediction was fulfilled because nearly all women
were shown to be infected with HPV, and HR types were
identified in most of them.
To determine HPV infection and to identify the high-risk
types involved we used the PCR-RFLP method based on
amplification of the E6-250 HR-HPV product followed by
digestion with endonucleases [19] and fragment sizing in
high resolution agarose gels [25]. Obtaining cervical
scrapings with the cytobrush allowed us to obtain more
than enough amplifiable DNA in nearly all samples and
PCR optimization assured efficient amplification with the
primer sets employed.
The E6-250 HR-HPV product was amplified through
nested PCR because this modality turned out to be at least
twice as sensitive as direct PCR. The universal primer sets
for the first ('direct') reaction amplified the E6-650 prod-
uct [19,26] and the primer set used in the second
('nested') reaction amplified the E6-250 product [27]. The
use of duplex PCR was discarded to amplify E6-250 and
L1-450 due to the interference observed when simultane-
ous amplification of both products was attempted (Fig.
4). The scarce E6-negative samples were tested later with a
universal primer set that amplifies L1-450 segments of
both low risk- as well as HR-HPV types [28]. From these
observations we concluded that to determine HR-HPV
infection in women with dysplasia and neoplasia it is con-
venient first to identify the HPV-positive samples and
then to check the amplificability of the negative ones.
Eight HR-HPV types (16, 18, 31, 33, 35, 45, 52 and 58) are
responsible for 95% of the invasive CC cases in the world
[14]. The PCR-RFLP used in this work identified all of
them except type 45.
Considering all cervical samples included in this work,
98.8% contained amplifiable DNA, 97.8% had HPV infec-
tions which in 90.2% of the cases corresponded to HR-
HPV types whose prevalence was higher in Gto (99.0%)
than in SLP (82.6%) (Table 3).
In the 437 samples with amplifiable DNA included in this
study, 528 cervical infections were demonstrated by HR-
HPV types that were identified in 99.1% of the cases
(Table 4). In this way we demonstrated that in our region
circulate the seven HR-HPV types identified with the
method used and their overall prevalence is, in descend-
ing order, 16 (53.4%) > 31 (15.6%) > 18 (8.9%) > 35
(5.6) > 52 (5.4%) > 33 (1.2%) > 58 (0.7%) = unidentified
types (0.7%). From these results we recommend that for
analysis of cervical samples with dysplasia it is convenient
to identify first the types 16, 18 and 33 by restriction with
Ava II and then the types 31, 35, 52 and 58 by restriction
with Rsa I, Ava I, Bgl II and Acc I.
The prevalence of high and low risk HPV types found by
us is similar to that already seen in Mexico and other
regions of high CC incidence [20,21,29]. The predomi-
nant HR-HPV types in our region are 16, 31 and 18 which
Table 4: Prevalence of single and multiple HR-HPV infections
Infections SLP Gto Overall
n% n% n%
Single 159 75.0 128 67.4 287 71.4
Double 48 22.6 56 29.5 104 25.9
Triple 5 2.4 6 3.2 11 2.7
Total 212 100.0 190 100.0 402 100.0
Table 3: Prevalence of HR-HPV types
HR-HPV type SLP Gto Overall
n%n%n%
16 169 53.3 138 52.9 307 53.4
31 32 10.1 58 22.3 90 15.6
18 28 8.8 23 8.8 51 8.9
35 15 4.7 17 6.5 32 5.6
52 16 5.1 15 5.7 31 5.4
33 3 0.9 4 1.6 7 1.2
58 4 1.3 0 0.0 4 0.7
NI 1 0.3 3 1.2 4 0.7
Total 268 84.5 258 99.0 526 91.4
NI, type not identified.Infectious Agents and Cancer 2008, 3:3 http://www.infectagentscancer.com/content/3/1/3
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together represent 77.9% of all cervical infections. The
four remaining types cause 12.9%, and unidentified types
only 0.7% of the HR-HPV infections. Types 16 and 18 are
slightly more prevalent in SLP, whereas type 31 is nearly
two times more prevalent in Gto.
The overall prevalence of HPV type 16 in our region
(53.4%) is almost identical to the world average (53%)
calculated by Munoz (2000). In contrast, the regional
prevalence of type 18 (8.9%) is substantially lower than
the world average (15%) calculated by Munoz [21]. The
prevalence of types 31 (15.6%) and 35 (5.6%) is higher
than the average for Latin America [21], whereas that of
type 33 (1.2%) is nearly 10 times lower than the average
for Central America (11.8%) recently obtained by Clifford
et al. [30].
Single and triple infections were more frequent in SLP,
whereas double infections were more frequent in Gto.
Single infections included all seven HR-HPV identifiable
types where the three predominant ones were, in descend-
ing order, 16 > 18 > 31 with a cumulative frequency of
92.7%. The prevalence of these types in SLP was, in
descending order, 16 > 18 > 31 with a cumulative fre-
quency of 95.0%, whereas in Gto it was 16 > 31 > 18 with
a cumulative frequency of 89.1%.
The typing method allowed us to identify a considerable
proportion of infections by two viral types (overall preva-
lence of 25.9%, with 22.6% for SLP and 29.5% for Gto)
and three viral types (overall prevalence of 2.7%, with
2.4% for SLP and 3.2% for Gto) (Table 4). Type 16 was
found in all multiple infections.
Table 5: Prevalence of HR-HPV types in single, double and triple infections
Infections HR-HPV ypes SLP Gto Overall
n% n% n%
Single 16 123 77.4 81 63.3 204 72.6
18 15 9.4 16 12.5 31 10.2
31 13 8.2 17 13.3 30 9.9
52 4 2.5 6 4.7 10 3.3
3 3 21 . 3 21 . 6 41 . 3
3 5 10 . 6 32 . 3 41 . 3
5 8 10 . 6 00 . 0 10 . 3
NI 0 0.0 3 2.3 3 1.0
Sum 159 100.0 128 100.0 287 100.0
Double 16/18 7 14.6 4 7.1 11 10.6
16/31 14 29.2 35 63.0 49 47.1
16/33 1 2.1 1 1.8 2 1.9
1 6 / 3 5 71 4 . 6 61 1 . 0 1 31 2 . 5
16/52 9 18.8 5 8.9 14 13.5
16/58 3 6.3 0 0.0 3 2.9
18/31 1 2.1 1 1.8 2 1.9
18/35 2 4.2 0 0.0 2 1.9
18/52 1 2.1 0 0.0 1 1.0
18/NI 1 2.1 0 0.0 1 1.0
31/33 0 0.0 1 1.8 1 1.0
31/35 1 2.1 1 1.8 2 1.9
35/52 1 2.1 2 3.6 3 2.9
Sum 48 100.0 56 100.0 104 100.0
Triple 16/31/52 2 40.0 1 17.0 3 27.3
16/18/35 1 20.0 2 33.0 3 27.3
16/31/35 1 20.0 2 33.0 3 27.3
16/35/52 1 20.0 1 17.0 2 18.2
Sum 5 100.0 6 100.0 11 100.0
Total 212 52.7 190 47.3 402 100.0
NI, type not identified.Infectious Agents and Cancer 2008, 3:3 http://www.infectagentscancer.com/content/3/1/3
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Table 7: HR-HPV types of single and multiple infections in lesions of increasing severity
Infections HR-HPV types LSIL HSIL Cancer Overall
n% n% n% n %
Single 16 149 38.9 37 9.7 17 4.4 203 53.0
18 21 5.5 0 0.0 1 0.3 22 5.7
31 17 4.4 5 1.3 4 1.0 26 6.8
33 0 0.0 1 0.3 2 0.5 3 0.8
35 4 1.0 1 0.3 1 0.3 6 1.6
52 7 1.8 1 0.3 1 0.3 9 2.3
58 1 0.3 0 0.0 0 0.0 1 0.3
Sum 199 52.0 45 11.7 26 6.8 270 70.5
Double 16/18 9 2.3 4 1.0 0 0.0 13 3.4
16/31 36 9.4 4 1.0 9 2.3 49 12.8
16/33 1 0.3 0 0.0 0 0.0 1 0.3
16/35 10 2.6 2 0.5 1 0.3 13 3.4
16/52 8 2.1 3 0.8 1 0.3 12 3.1
16/58 2 0.5 1 0.3 0 0.0 3 0.8
18/35 3 0.8 0 0.0 1 0.3 4 1.0
18/NI 1 0.3 0 0.0 0 0.0 1 0.3
31/33 0 0.0 1 0.3 0 0.0 1 0.3
31/35 2 0.5 0 0.0 0 0.0 2 0.5
31/52 1 0.3 1 0.3 0 0.0 2 0.5
35/52 0 0.0 1 0.3 0 0.0 1 0.3
Sum 73 19.1 17 4.4 12 3.1 102 26.6
Triple 16/18/35 1 0.3 1 0.3 0 0.0 2 0.5
16/31/35 2 0.5 1 0.3 1 0.3 4 1.0
16/31/52 2 0.5 0 0.0 0 0.0 2 0.5
16/35/52 2 0.5 0 0.0 0 0.0 2 0.5
18/31/52 1 0.3 0 0.0 0 0.0 1 0.3
Sum 8 2.1 2 0.5 1 0.3 11 2.9
Total 280 73.1 64 16.7 39 10.2 383 100.0
Table 6: Prevalence (%) of HR-HPV types in single, double and triple infections
HR-HPV types SLP Gto Overall
Single Double Triple Single Double Triple Single Double Triple
16 77.4 85.4 100.0 36.7 91.1 100.0 71.1 88.5 100.0
18 9.4 25.0 20.0 10.0 8.9 33.3 10.8 16.3 27.3
31 8.2 33.3 40.0 16.7 78.6 50.0 10.5 57.7 45.5
52 2.5 20.8 60.0 16.7 12.5 33.3 3.5 16.3 45.5
33 1.3 2.1 0.0 0.0 3.6 0.0 0.0 2.9 0.0
35 0.6 22.9 60.0 20.0 16.1 50.0 1.4 19.2 54.5
58 0.6 6.3 0.0 0.0 0.0 0.0 0.3 2.9 0.0
NI 0.0 2.1 0.0 0.0 0.0 0.0 1.0 1.0 0.0
NI, type not identified.Infectious Agents and Cancer 2008, 3:3 http://www.infectagentscancer.com/content/3/1/3
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Double infections from SLP were caused by the seven
identifiable types but type 58 was absent in Gto. The over-
all predominant types in double infections were 16 > 31 >
35 > 18 = 52. Their prevalence differed in each state since
the descending order in SLP was 16 > 31 > 18 > 35 > 52,
whereas in Gto it was 16 > 31 > 35 > 52 > 18 (Table 6).
Types 33 and 58 were absent from triple infections in both
states and the overall predominant types were 16 > 35 >
31 = 52 > 18. There were also differences in the prevalence
by state since in SLP the descending order was 16 > 35 =
52 > 31 > 18 whereas in Gto it was 16 > 35 = 52 > 31 > 18
(Table 6).
Our algorithm for typing, designed to identify first the
high-risk viral types and then the low risk ones, probably
underestimates the prevalence of low risk types in samples
where high risk types are demonstrated. However, it is
worth noting that in low grade intraepithelial cervical
lesions practically all genital HPV types are found,
whereas in high grade lesions only high risk types are
found [31].
The proportion of multiple infections found by us
(28.6%) is over three times higher than the world average
(8.1%) calculated by Molano et al. [32]. This feature is
probably due to the fact that the women in our study are
themselves a high risk group since they were included for
having cervical dysplasia and cancer. This idea is rein-
forced by our finding that 10.6% of the double infections
are due to the 16/18 type couple, whose prevalence was
nearly six times higher than the world average (1.8%) esti-
mated by Clifford et al. [30].
The five predominant HR-HPV types (16, 31, 18, 35 and
52) found in the 140 HSIL and invasive cancer lesions
accounted for 92.9% of the cases and their frequency was
similar to their overall prevalence (Table 9).
Infections by two or more HPV types are markers of per-
sistent cervical disease, of multiple cervical lesions and of
progression from low to high grade lesions [33]. There is
scarce evidence on the interaction of HPV types to
enhance CC pathogenesis and it is unknown if some HPV
types promote or exclude infection by others. Careful fol-
low up of multiple infections may help to pinpoint the
relevance of the interactions of different HPV types in dis-
ease progression [34].
HPV16, the most frequent type in single and multiple
infections in SLP and Gto, just as in the rest of the world
[14,21] appears to be the most persistent type [32,35,36]
increasing the risk of developing severe preneoplastic
lesions [37].
Our work confirms the usefulness of the PCR-RFLP
method of Fujinaga et al. [19,26,27] for diagnosis and typ-
ing cervical infections by HR-HPV, whose sensitivity was
at least doubled by amplifying the E6-250 product
through nested rather than direct PCR and whose typing
precision was improved by using high resolution electro-
phoresis. In this way we could identify the HR-HPV types
circulating in our region and their distribution in the two
neighboring states analyzed, which reflect the endemic
behavior of the various HPV types as well as local environ-
mental or genetic conditions of the hosts [38].
Besides being of use to carry out molecular epidemiology
studies and to predict the individual risk of each patient,
HR-HPV typing is essential to plan the administration of
prophylactic vaccines directed against one or more spe-
cific HPV types, which is questionable in populations
where prevalence of the circulating types is unknown
[31,39,40]. Since in our region HPV type 16 has the high-
est overall prevalence (53.4%), type 31 is second (15.6%)
and type 18 is third (8.9%), the vaccine against HR-HPV
types 16 and 18 [41] whose license was granted first in
Mexico and the United States [42,43] would be expected
Table 8: Frequency of single and multiple HR-HPV infections in 
lesions of increasing severity
Lesion Type of infection S/M ratio
Single (S) Multiple (M) Overall
n%n %n %
LSIL 199 52.0 81 21.1 280 73.1 2.46
HSIL 45 11.7 19 5.0 64 16.7 2.37
Cancer 26 6.8 13 3.4 39 10.2 2.00
Total 280 70.5 113 29.5 383 100.0 ---
LSIL, low-grade squamous intraepithelial lesion.
HSIL, high-grade squamous intraepithelial lesion.
Table 9: HR-HPV types in HSIL and invasive cancer lesions
HR-HPV type Frequency (%) O/H ratio
Overall (O) In HSIL and cancer (H)
16 53.4 55.0 0.97
31 15.6 18.6 0.84
18 8.9 4.3 2.07
35 5.6 7.9 0.71
52 5.4 7.1 0.76
33 1.2 2.9 0.41
58 0.7 0.7 1.00
NI 0.7 3.6 0.19
NI, type not identified.Infectious Agents and Cancer 2008, 3:3 http://www.infectagentscancer.com/content/3/1/3
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to cover at least these three types [44] and would have a
78% efficacy.
Conclusion
Enough DNA is obtained from cervical scrapings of
women with dysplasia in order to detect high risk-HPV by
PCR amplification followed by typing through restriction
fragment length polymorphism analysis.
Sensitivity of HR-HPV detection is nearly doubled by
nested rather than direct PCR amplification.
Ninety-two percent of the 437 Mexican women with cer-
vical dysplasia and cancer included in this study were
infected by HR-HPV, with a prevalence 1.14 times higher
in the state of Guanajuato than in San Luis Potosí.
All seven HR-HPV types identifiable with the method
used (16, 18, 31, 33, 35, 52, 58) circulate in SLP and Gto
and were diagnosed in nearly all (99.3%) the cases.
Seventy-one percent of the infections were caused by one
HR-HPV type, 25.9% by two types and 2.7% by three
types.
The overall frequency of cervical lesions was LSIL (73.1%)
> HSIL (16.7%) > invasive cancer (10.2%) and the ratio of
single to multiple infections was inversely proportional to
the severity of the lesions: 2.46 for LSIL, 2.37 for HSIL and
2.15 for invasive cancer.
The frequency of HR-HPV types found in HSIL and inva-
sive cancer was 16 (55.0%) > 31 (18.6%) > 35 (7.9%) >
52 (7.1%) > 18 (4.3%) > unidentified types (3.6%) > 33
(2.9%) > 58 (0.7%).
Since the three predominant HR-HPV types found (16, 31
and 18) cause 77.9% of the HR-HPV infections associated
to cervical dysplasia in this region, and immunization
against type 16 prevents type 31 infections, in this region
the efficacy of the prophylactic vaccine against types 16
and 18 would be close to 80%.
Methods
Source of women
The 442 women included in this study were selected for
having precancerous or cancerous lesions of the cervical
epithelium confirmed by cytologic analysis. Two hundred
and eighteen resided in the city of San Luis Potosí, capital
of the state of San Luis Potosí (SLP), and 192 in the cities
of León, Celaya and Irapuato from the state of Guanajuato
(Gto), Mexico. Cervical scrapings from SLP were obtained
at the Dysplasia Clinic of the SLP Health Services, the
School of Nursing of Universidad Autónoma de San Luis
Potosí, and from private patients. Samples from Gto were
obtained at the Dysplasia Clinics of the cities of Irapuato,
Celaya and León and sent to our laboratory by the Guana-
juato Health Secretariat. The study was authorized by the
Health Secretariats of SLP and Gto and performed with
the informed consent of all participating women.
Cervical scrapings and DNA extraction
Each scraping was taken with an endocervical brush
('cytobrush') that was immediately inserted in a 5 ml
polypropylene tube (Nalge Nunc, Rochester, NY) contain-
ing 1 ml phosphate buffered saline supplemented with
sterile disodium ethtylene-diamino-tetraacetate (PBS-
EDTA: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2
mM KH2HPO2, 25 mM disodium EDTA, pH 7.4). Once
detached from the cytobrush and suspended in the PBS-
EDTA vehicle, each sample was fixed by addition of 1.5 ml
96% ethanol and processed to extract DNA on the same
day or up to 30 days after being kept at room temperature.
Reagents were purchased from J.T. Baker (Xalostoc, Méxi-
co) unless other source is specified.
To extract the DNA each fixed sample was mixed by vor-
texing and 1 ml transfered to a 1.5 ml tube and spun in a
Hettich Mikro 20 microcentrifuge (Cologne, Germany)
for 5 min at 13,000 rpm (16,250×g). The supernatant was
discarded by decantation and to each pellet were added
500 μl of Tris-EDTA-saline (TES: 10 mM Tris-HCl; 2 mM
Inhibition of L1-450 and E6-250 segment amplification in  duplex PCR mixtures with primer sets MY 09/11 and pU 1M/ 2R Figure 4
Inhibition of L1-450 and E6-250 segment amplifica-
tion in duplex PCR mixtures with primer sets MY 09/
11 and pU 1M/2R. Mixtures contained 50 ng DNA from 
Patient 1 as well as primer set MY 09/11, pU 1M/2R, or both. 
Arrows to the left indicate positions of the bands expected. 
Lane 1, 100 bp ladder. Lane 2, Uniplex 1 mixture (set MY 09/
11). Lane 3, Uniplex mixture 2 (set pU 1M/2R). Lane 4, 
Duplex mixture (sets MY 09/11 and pU 1M/2R). Lane 5, Neg-
ative control (without DNA). Major bands expected in uni-
plex and duplex mixtures: ~450 bp with set MY 09/11 (Lanes 
2 and 4) and ~250 bp with set pU 1M/2R (Lanes 3 and 4). 
Note the decrease in the intensity of bands in the duplex 
mixture (lane 4), especially ~450 bp.
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disodium EDTA, 0.4 M NaCl, pH 8.0 at 25°C), 50 μl of
10% sodium dodecyl sulphate and 20 μl of proteinase K
(20 mg/ml). Mixtures were incubated at 55°C for 3 h, at
the end of which 150 μl of 5 M NaCl were added and cen-
trifuged again for 15 min. Each supernatant was aspirated
and transferred to a tube to which 577 μl cold isopropa-
nol were immediately added and then left stand for 10
min at 4°C to precipitate the nucleic acids. The tubes were
centrifuged again for 10 min and supernatants discarded
by decantation. Each pellet was washed by vortexing with
1 ml of 70% cold ethanol and centrifuged for 10 min at
10,000 rpm (9,615×g) and room temperature. Superna-
tants were discarded by aspiration and the pellets dried
out by inverting the tubes for 15 min on a paper towel.
Each pellet was dissolved with 50 μl TE (10 mM Tris-HCl,
1 mM disodium EDTA, pH 8.0 at 25°C).
The quality of extracted DNA was verified by electro-
phoretic analysis in 1% agarose gels with TAE (40 mM
Tris-acetate, 1 mM disodium EDTA, pH 8.2 at 25°C).
Two-μl from each sample were applied to gels which were
run at 60 V for 90 min. λ-phage? DNA digested with Hind
III (Sigma-Aldrich, Mexico) was used as marker. After
staining for 20 min with ethidium bromide (1 μg/ml) gels
were illuminated with ultraviolet light and their fluores-
cence recorded with the Bio-Rad ChemiDoc EQ (Her-
cules, CA) photo documenter.
DNA was quantitated by fluorometry with the PicoGreen
dsDNA Quantitation kit (Molecular Probes; Eugene, OR)
by interpolation in a standard curve containing up to 50
ng of λ-phage DNA. To each well of a black FIA 96 well
plate (Greiner Bio-One, Frickenhausen, Germany) 198 μl
of the assay solution (PicoGreen diluted 1:400 in TE) and
2 μl of standard DNA or problem samples were added,
and their fluorescence determined using a 485 nm excita-
tion filter and a 535 emission filter in the GENios Pro
fluorometer (Tecan Systems, San Jose, CA) with the Mag-
ellan 4 software.
Since amplification of the β-globin gene required = 25 ng
DNA per PCR mixture, 100 ng was the minimum amount
of DNA required from each cervical scraping in order to
prepare at least four PCR mixtures.
The range of pure DNA obtained from the first 370 cervi-
cal scrapings was 53–16,590 ng. The amount of purified
DNA was sufficient (i.e., = 100 ng) in all samples except
five of the initial ones.
PCR conditions
The oligonucleotide primer sets and the sizes expected for
the HPV amplification products are depicted in Table 10.
To optimize PCR with each primer set variable DNA and
MgCl2 concentrations and annealing temperatures were
tested. The β-globin primer set was added to PCR mixtures
containing double-serial dilutions of DNA from a HPV-
positive sample (range: 0.78–50 ng). To optimize condi-
tions for HPV primer sets, 1–5 mM MgCl2 concentrations
and annealing temperatures from 55°C to 61.4°C were
tested.
To maximize HPV detection through PCR amplification,
three variables were optimized: DNA content, annealing
temperature and magnesium concentration.
With the PC04/GH20 primer set for β-globin the mini-
mum amount of template DNA required in PCR mixtures
was determined with double serial dilutions leading to a
maximum of 50 ng DNA per mixture. Fluorescence of the
E6-250 product increased with DNA content up to 25 ng,
which was the amount selected to amplify HPV DNA from
each sample. Annealing temperature in the range of 55°C
to 62°C was assessed with each primer set. As major prod-
ucts attained maximum fluorescence at 57°C this anneal-
Table 10: Oligonucleotides used
Oligonucleotides Gene amplified Amplicon size
Set Name Sequence (5' → 3') Positiona
1b LCRS AAGGGAGTAACCGAAAACGGT 26 E6 ~650 bp
E7AS TCATCCTCCTCCTCTGAG 671
2b pU1M TGTCAAAAACCGTTGTGTCC 419 E6 ~250 bp
pU2R GAGCTGTCGCTTAATTGCTC 656
3b MY09 CGTCCMARRGGAWACTGATC 6584 L1 ~450 bp
MY11 GCMCAGGGWCATAAYAATGG 7035
4c PC04 CAACTTCATCCACGTTCAACC --- β-globin ~260 bp
GH20 GAAGAGCCAAGGACAGGTAC ---
a Nucleotide of the HPV16 genome at which the 5' end of each primer is bound.
b Fujinaga et al. [19].
c Sotlar et al. [46].Infectious Agents and Cancer 2008, 3:3 http://www.infectagentscancer.com/content/3/1/3
Page 12 of 13
(page number not for citation purposes)
ing temperature was used with all primer sets for the rest
of the work. MgCl2 concentrations in the 1–5 mM range
were tested. Maximum efficiency was attained at 2.5 mM,
concentration chosen for the rest of the work.
The primer set LCRS/E7AS amplifies the E6-650 segment
and the set pU 1M/2R amplifies the 'nested' E6-250 seg-
ment included in the first one. In the HPV16 genome, the
set LCRS/E7AS spans nucleotides 26–671 (645 bp) and
the set pU 1M/2R spans nt 419–656 (237 bp). The set MY
09/11 amplifies the L1-450 segment which spans nt
6584–7035 (451 bp). To explore the feasibility of using
duplex PCR to simultaneously amplify E6-250 with
primer set pU 1M/2R and L1-450 with primer set MY 09/
11, we tested both sets at 0.6 μM concentration. However,
our finding that in duplex mixtures the L1-450 band was
nearly lost and the E6-250 band was less intense than in
uniplex mixtures (Fig. 4) led us to discard the use of
duplex mixtures.
Detection of the HPV DNA amplification products
LCR/E7 ~650 bp (E6-650), E6/E7 ~250 bp (E6-250) and
L1 ~450 bp (L1-450) products were amplified with primer
sets pU 1M/2R, LCRS/E7AS and MY 09/11, respectively
(Table 7). Each 50 μl PCR mixture was prepared in 200 μl
Axygen tubes (Union City, CA). PCR mixtures contained
2.5 mM MgCl2, 0.4 mM of each dNTP, 0.6 μM of each oli-
gonucleotide, 1.5 units of recombinant Taq DNA
polymerase and 25 ng DNA, 20 mM Tris-HCl, 50 mM
KCl, pH 8.4 at 25°C; oligonucleotides were synthesized
by Accesolab (Mexico) and other components were pur-
chased from Invitrogen (Mexico).
PCR mixtures were incubated 40 cycles in a Techne Touch-
gene Gradient thermocycler (Staffordshire, England).
Before starting they were incubated at 94°C for 4 min.
Each cycle consisted of 1 min periods at 94°C (denatura-
tion), 57°C (annealing) and 72°C (extension), followed
by 10 min final extension at 72°C. Each run included a
positive control with 25 ng of HeLa cell DNA known to
contain 10–50 copies of the HPV type 18 genome per cell
[45], and a negative control with water instead of DNA.
PCR products (10 μl from each mixture) were subjected to
electrophoresis in 1.5% agarose gels with 5 mM sodium
borate, pH 8.5 [25] that were run at 120 V for 90 min.
High-risk HPV typing
To identify HR-HPV types the method of Fujinaga et al.
[19] was used. The size of the two E6-250 restriction frag-
ments generated with endonucleases for each of the seven
HR-HPV types that can be identified with this method are
shown in Table 2.
Ava I, Ava II and Bgl II endonucleases and their buffers
were purchased from Biolabs (Beverly, MA), whereas Rsa
I and Acc I and their buffers were obtained from Invitro-
gen (Carlsbad, CA). Digestion mixtures containing 8 μl of
PCR amplification mixture, 1.5 μl endonuclease solution
(10 U/μl), 2 μl buffer and 8.5 μl water were incubated 3 h
at 37°C. The restriction fragments present in 10 μl from
each digestion mixture were analyzed by electrophoresis
in 2% agarose gels with 5 mM sodium borate, pH 8.5
(Brody and Kern 2004) that were run at 120 V for 90 min.
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